Effects of enalapril on disseminated intravascular thrombin formation during systemic inflammation

Cardiovascular Research

Volumn 60, Issue 1, 2003, Pages 131-135

  Marsik, Claudia ^a   Graninger, Monika ^a   Mackman, Nigel ^b   Osterud, Bjarne ^c   Luther, Thomas ^d   Jilma, Bernd ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TROMSØ   (Norway)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Angiotensin converting enzyme; D Dimer; Enalapril; Endotoxins; Prothrombin fragment; Randomised controlled trial

Indexed keywords

ANTIPLASMIN; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; ENDOTOXIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PLACEBO; PLASMIN; PROTHROMBIN; THROMBIN; THROMBOPLASTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; INFUSION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SYNTHESIS; VOLUNTEER; ANALYSIS OF VARIANCE; BLOOD; CHEMISTRY; DISSEMINATED INTRAVASCULAR CLOTTING; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGY; MONONUCLEAR CELL; NONPARAMETRIC TEST;

ADULT; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISSEMINATED INTRAVASCULAR COAGULATION; ENALAPRIL; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; PLASMIN; PROTHROMBIN; STATISTICS, NONPARAMETRIC; THROMBOPLASTIN;

EID: 0642342934     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00363-8     Document Type: Article

References (32)

1. Blann A.D., Lip G.Y. Relation between endothelial-cell activation and infection, inflammation, and infarction. Lancet. 350:1997;293-294.
2. Meier C.R., Jick S.S., Derby L.E., Vasilakis C., Jick H. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet. 351:1998;1467-1471.
3. Vallance P., Collier J., Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet. 349:1997;1391-1392.
4. Zeuke S., Ulmer A.J., Kusumoto S., Katus H.A., Heine H. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res. 56:2002;126-134.
5. Opal S.M. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med. 28:2000;S77-80.
6. Derhaschnig U., Laggner A.N., Roggla M., et al. Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room. Clin Chem. 48:2002;1924-1930.
7. Lopez-Aguirre Y., Paramo J.A. Endothelial cell and hemostatic activation in relation to cytokines in patients with sepsis. Thromb Res. 94:1999;95-101.
8. Reinhart K., Bayer O., Brunkhorst F., Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med. 30:2002;S302-312.
9. van der Poll T., Calvano S.E., Kumar A., et al. Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood. 86:1995;2754-2759.
10. Kerr R., Stirling D., Ludlam C.A. Interleukin 6 and haemostasis. Br J Haematol. 115:2001;3-12.
11. Osterud B. Tissue factor: a complex biological role. Thromb Haemost. 78:1997;755-758.
12. Moons A.H., Levi M., Peters R.J. Tissue factor and coronary artery disease. Cardiovasc Res. 53:2002;313-325.
13. Napoleone E., Di Santo A., Camera M., Tremoli E., Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res. 86:2000;139-143.
14. Altavilla D., Squadrito G., Minutoli L., et al. Inhibition of nuclear factor-kappaB activation by IRFI 042, protects against endotoxin-induced shock. Cardiovasc Res. 54:2002;684-693.
15. Suffredini A.F., Hochstein H.D., McMahon F.G. Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis. 179:1999;1278-1282.
16. de Jonge E., Dekkers P.E., Creasey A.A., et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 95:2000;1124-1129.
17. Franco R.F., de Jonge E., Dekkers P.E., et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood. 96:2000;554-559.
18. Jilma B., Marsik C., Mayr F., et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther. 72:2002;403-410.
19. Hollenstein U., Homoncik M., Stohlawetz P.J., et al. Endotoxin down-modulates granulocyte colony-stimulating factor receptor (CD114) on human neutrophils. J Infect Dis. 182:2000;343-346.
20. Jilma B., Marsik C., Mayr F., Graninger M.T., et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther. 72:(4):2002;403-410.
21. Jilma B., Dirnberger E., Loscher I., et al. Menstrual cycle-assoicated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein. J Lab Clin Med. 130:(1):1997;69-75.
22. Albrecht S., Kotzsch M., Siegert G., et al. Detection of circulating tissue factor and factor VII in a normal population. Thromb Haemost. 75:1996;772-777.
23. Stolley P.D., Strom B.L. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther. 39:1986;489-490.
24. Osterud B. Tissue factor expression in monocytes: in vitro compared to ex vivo. Thromb Haemost. 84:2000;521-522.
25. Buchan K.W., Pike N.B., Sumner M.J. Sodium salicylate enhances expression of tissue factor (TF) in human adherent monocytes and in whole blood. Thromb Haemost. 80:1998;346-347.
26. Oeth P., Mackman N. Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells. Blood. 86:1995;4144-4152.
27. Osnes L.T., Foss K.B., Joo G.B., et al. Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-kappa B/c-Rel nuclear translocation, and synthesis of tissue factor (TF) and tumor necrosis factor alpha (TNF-alpha) in human monocytes. Thromb Haemost. 76:1996;970-976.
28. Osterud B., Olsen J.O., Wilsgard L. Increased lipopolysaccharide-induced tissue factor activity and tumour necrosis factor production in monocytes after intake of aspirin: possible role of prostaglandin E2. Blood Coagul Fibrinolysis. 3:1992;309-313.
29. Huang C.M., Young M.S. Long-term survival of non-elderly patients with severe heart failure treated with angiotensin-converting enzyme inhibitors assessment of treatment with captopril and enalapril survival study (ACESS). Circ J. 66:2002;886-890.
30. Packer M., Califf R.M., Konstam M.A., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 106:2002;920-926.
31. Nanas J.N., Alexopoulos G., Anastasiou-Nana M.I., et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group. J Am Coll Cardiol. 36:2000;2090-2095.
32. Eriksson M., Saldeen T. Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat. Int J Microcirc Clin Exp. 8:1989;245-258.